問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Urology

Division of General Internal Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

蔡育賢Tsai, Yuh-Shyan
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

48Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡育賢

List

66Cases

2024-11-01 - 2031-09-30

Phase III

Active
A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    錠劑 軟膠囊劑

Participate Sites
5Sites

Recruiting5Sites

2025-08-01 - 2035-08-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Mevrometostat (PF-06821497) With Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer (MEVPRO-3)

  • Condition/Disease

    Metastatic Castration Sensitive Prostate Cancer (mCSPC)

  • Test Drug

    Tablets Capsules

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2029-09-30

Phase III

Active
A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

  • Condition/Disease

    Metastatic Castrate Resistant Prostate Cancer (mCRPC)

  • Test Drug

    錠劑 軟膠囊劑 輸注液

Participate Sites
6Sites

Recruiting6Sites

2022-07-01 - 2027-12-31

Phase III

Active
Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.

  • Condition/Disease

    Advanced Malignancies NS

  • Test Drug

    Avelumab (MSB0010718C)PF-04518600 (OX-40)Utomilumab (PF-05082566)

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2021-12-30 - 2027-04-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2015-12-01 - 2028-12-29

Phase III

Active
A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    JNJ-56021927

Participate Sites
7Sites

Terminated6Sites

馮思中
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2025-11-01 - 2030-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-01-01 - 2029-10-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-10-30 - 2022-12-31

Phase III

Completed
A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations

  • Condition/Disease

    Urothelial Cancer

  • Test Drug

    Erdafitinib

Participate Sites
12Sites

Recruiting2Sites

Terminated10Sites

吳文正
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

2017-06-01 - 2021-01-06

Phase II

Completed
A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies

  • Condition/Disease

    Metastatic Castration-Resistant Prostate Cancer

  • Test Drug

    Niraparib

Participate Sites
7Sites

Terminated7Sites

1 2 3 4 5 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB